My Healthcare News & Research — February 9, 2026 · Shingles Vaccine Linked to Lower Dementia Risk in 329,000 Adults

On February 9, 2026, researchers at Kaiser Permanente Southern California published a large study in Nature Communications reporting that adults who received the recombinant shingles vaccine (Shingrix) went on to be diagnosed with dementia far less often than comparable adults who did not. It is the newest and one of the largest entries in a fast-growing body of evidence that a routine shingles shot may do something for the brain. The finding is genuinely important — and, as this article explains carefully, it is an association, not yet proof that the shot prevents dementia.

Table of Contents

  1. 1. What the Study Found
  2. 2. How the Study Was Done
  3. 3. Why a Shingles Shot Might Protect the Brain
  4. 4. The Honest Caveats
  5. 5. What This Means for You
  6. Sources
  7. Connections
  8. Featured Videos

1. What the Study Found

The headline number is striking. Among adults aged 65 and older, two doses of the recombinant zoster vaccine were associated with a 51% lower risk of a new dementia diagnosis over the follow-up period (adjusted hazard ratio 0.49, 95% confidence interval 0.46–0.51). The protection appeared across age, racial, and ethnic groups, and it was stronger in women (about 55% lower risk) than in men (about 45%) — a sex difference that has now shown up in several independent shingles-vaccine-and-dementia studies and remains unexplained.

A 51% reduction is a very large effect for any preventive measure, and that size is itself a reason for caution rather than celebration. As the sections below explain, part of that number almost certainly reflects the fact that people who choose to get vaccinated tend to be healthier and more engaged with medical care to begin with. The honest read is that the true protective effect is probably real but smaller than the raw 51% headline.

2. How the Study Was Done

This was a retrospective matched-cohort study built from Kaiser Permanente's electronic health records. The team, led by Emily Rayens, identified 65,800 people who completed the two-dose Shingrix series between April 2018 and December 2020 and matched each of them to four similar unvaccinated members — 263,200 comparators, for a total of roughly 329,000 adults — then followed everyone for new dementia diagnoses through the end of 2023.

The most valuable part of the paper is not the headline but the work the authors did to attack their own result. The central worry in any study like this is healthy-vaccinee bias: the people who show up for an optional vaccine are, on average, more health-conscious, better connected to primary care, and less frail than those who skip it — and all of those traits independently lower dementia risk. To test whether that bias explained everything, the researchers compared Shingrix recipients against people who received a different routine vaccine (Tdap) rather than against the unvaccinated. If the whole effect were just "vaccinated people are healthier," the two vaccinated groups should look the same. They did not: Shingrix recipients still had a 27% lower dementia risk than Tdap recipients (hazard ratio 0.73). A separate "negative-control outcome" analysis — checking that the vaccine was not linked to unrelated conditions it has no plausible reason to affect — also supported the conclusion that leftover confounding is modest.

3. Why a Shingles Shot Might Protect the Brain

There are two leading biological explanations, and they are not mutually exclusive. The first is virus-specific: shingles is caused by reactivation of the varicella-zoster virus, the same virus that causes chickenpox and then hides in nerve cells for life. Reactivation drives inflammation in and around nerves, and a growing literature links herpes-family viral reactivation to the amyloid and neuroinflammatory processes seen in Alzheimer's and vascular dementia. By preventing reactivation, the vaccine may remove a recurring inflammatory hit to the aging brain.

The second explanation is non-specific: Shingrix contains a powerful immune adjuvant (AS01), and adjuvanted vaccines can produce broad "trained immunity" and off-target immune effects that dampen chronic inflammation. This second idea is attractive because it could explain why the protective signal for dementia has appeared with more than one type of shingles vaccine, and why the effect seems larger than a single virus alone would predict. Which mechanism dominates — or whether the truth is some mix — is not yet settled.

4. The Honest Caveats

This is the part that matters most, because the topic is easy to over-sell.

  1. It is observational, not a randomized trial. No one was assigned by coin flip to get the vaccine. Matching and the Tdap comparison reduce bias but cannot eliminate it the way randomization would.
  2. The best causal evidence points to a smaller effect. A landmark 2025 study in Nature exploited a quirk in Wales, where eligibility for the older live shingles vaccine was set by an exact date-of-birth cutoff — effectively a natural randomized experiment. That design, which is far more resistant to healthy-vaccinee bias, found roughly a one-fifth (about 20%) relative reduction in dementia, not a halving. The new Kaiser study concerns the newer recombinant vaccine and finds a larger association, but the causal Welsh number is the more conservative anchor.
  3. Association is not proof. These studies show that vaccinated people develop dementia less often. They do not prove the shot is the reason, and they cannot tell an individual how much their own risk would change.
  4. Follow-up is still relatively short for a disease that develops over decades, and diagnosis timing in health records is imperfect.

5. What This Means for You

The practical takeaway is refreshingly simple. If you are 50 or older (or immunocompromised and 19 or older), U.S. guidelines already recommend the two-dose recombinant shingles vaccine — not to prevent dementia, but because shingles itself is common, painful, and can lead to months of postherpetic neuralgia and other complications. That recommendation stands on its own.

What this new study adds is a plausible, increasingly well-supported bonus: the same shot you would get anyway to avoid shingles may also lower your odds of dementia. That is a good reason to stop putting off a vaccine you were already meant to receive. It is not a reason to treat the shot as a proven dementia drug, to skip other brain-health basics, or to expect a 50% personal risk cut. Talk with your clinician about whether you are due for the vaccine; the shingles protection alone makes the visit worthwhile, and the emerging dementia signal is a welcome — if still unproven — extra.

Sources

  1. Rayens E, et al. Recombinant zoster vaccine is associated with a reduced risk of dementia. Nature Communications. February 9, 2026. Kaiser Permanente Southern California. DOI: 10.1038/s41467-026-69289-0 · Full text: nature.com/articles/s41467-026-69289-0 · PMC12949228
  2. Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025;641(8062):438. The Welsh date-of-birth-cutoff study that provides the strongest causal evidence to date. DOI: 10.1038/s41586-025-08800-x
  3. CIDRAP (University of Minnesota) news coverage of the shingles-vaccine-and-dementia literature. cidrap.umn.edu
  4. PubMed topic search: recombinant zoster vaccine dementia

Connections

Back to Table of Contents